Intensification using peripheral blood stem cells collected after chemotherapy followed by growth factors is being increasingly investigated as an alternative to conventional chemotherapy for mantle cell non-Hodgkin lymphoma. We investigated 14 grades III-IV, t(11;14)-positive cases for contamination of PBSC collected after a polychemotherapy regimen followed by G-CSF. Patients were first treated with a polychemotherapy regimen. There were four CR, seven PR, two refractory and one early death. Seven patients have been transplanted, in whom PBSC were mobilized, using either cyclophosphamide/VP16 or Dexa-BEAM followed by G-CSF. For all patients, whether actually autografted or not, PB cells were tested at the time of regeneration on G-CSF after the first polychemotherapy or after the mobilizing regimen. PCR evaluation of contamination was performed first by a semi-quantitative approach, using serial dilutions of initial DNA, then confirmed using a limiting-dilution analysis. Two patients were not informative (one early death and one without an available molecular marker). PB cells collected at regeneration contained at least one log more lymphoma cells than steady-state blood or marrow, apart from in two cases. Moreover, where a mobilizing treatment diminished tumor burden in the patient, at the same time it increased PB contamination in most cases. We conclude that advanced mantle cell NHL appears to be largely resistant to significant in vivo purging by conventional chemotherapy. Where treatment brings benefits by reducing tumor load, it may at the same time negate it by mobilizing malignant cells into the collections used to intensify. Although the clonogenic potential of this massive infiltration is unknown (only gene marking studies could provide a definitive answer regarding the source of relapses), strategies aimed at reducing the level of contamination in the graft should be considered when designing future protocols.
Mantle cell lymphoma (MCL), is a subtype of non-Hodgkin's lymphoma (NHL), characterized by distinct morphologic, immunophenotypic, 1,2 cytogenetic 3 and molecular features. 4, 5 It is recognized as an incurable disease by conventional therapy, with a rather poor long-term survival. [6] [7] [8] High-dose chemo-radiotherapy (HDCT) with autologous stem cell transplantation (ASCT) is a potentially curative modality for aggressive NHL, 9, 10 and many investigators have focused on this type of treatment to try to improve the outcome of MCL. The patients are usually given several courses of chemotherapy, sometimes followed by a more intensive regimen, both to further reduce the tumour burden and to mobilize peripheral blood progenitor cells (PBPC) using growth factors. A final HDCT with PBPC support [11] [12] [13] [14] [15] [16] [17] [18] [19] is then performed. However, the results achieved using this form of treatment, although interesting, have not to date proven superior to those achieved with more conventional treatment. 6, 7 Moreover, some discrepancies can be found between reports concerning achievement of long-term disease-free survival (DFS), projected overall survival, varying from 24% 16 at 3 years to 62% at 4 years, 14 based on small numbers of patients. It is worth mentioning that in the latter study, in vitro purging of the graft was used, which raises the question, also alluded to by other authors, 15, 18 of whether patients transplanted with a graft free (or PCR-free) of lymphoma cells, will achieve prolonged DFS. This possibility that patients in whom no (or fewer) lymphoma cells are reinfused could do better and the lack of quantitative data in the literature, led us to evaluate the effects of contamination of blood or marrow by lymphoma cells, although, in this chemoresistant disease, separating the effect on outcome of residual MCL cell in the patient and MCL cells reinfused is difficult.
We therefore assessed 14 advanced MCL patients for the presence of lymphoma cells during chemotherapy and at the time a stem cell collection was undertaken or could have been undertaken (regeneration of chemotherapy on growth factors) if ASCT was not planned or not feasible.
Patients and methods

Patients
Fourteen patients (age 36-66) with bulky stage III or stage IV MCL were investigated for residual disease (MRD) dur-ing the course of their treatment. The diagnosis of MCL was made by morphologic and immunologic analysis according to the REAL classification criteria 1 and further confirmed by cytogenetic analysis 3 -detection of a t(11;14) translocation -or molecular demonstration of cyclin D1 hyperexpression according to the methodology described by Uchimaru et al. 5 Treatment (first-line for all but one patient) was first a polychemotherapy regimen (CHVP, three; CHOP, nine; ACVBP, one; DHAP, one in first relapse), followed by a mobilizing regimen in patients to be transplanted (CPM-VP16, four patients; DEXA-BEAM, three patients) with PBSC collected during regeneration with G-CSF (5 g/kg). The conditioning regimen was BEAM for the seven patients currently autografted. Reasons for not transplanting the seven remaining were refusal one, death two, progressive two and age above 65 or bad ECOG status two.
Samples
Peripheral blood mononuclear cells were assessed for all the patients, whether actually autografted or not, at the end of the chemotherapy cycles (REG-PB) during which G-CSF was given to shorten the neutropenic period. Samples were taken when WBC count rose to 2-3 × 10 9 /l on G-CSF, and were compared to steady-state bone marrow (S-S BM) or peripheral blood (S-S PB) samples drawn 1-2 weeks later.
In patients to be transplanted, MRD was measured in PBPC harvests after the mobilizing regimen and compared to S-S PB and S-S BM before and after this course of treatment, in order to distinguish the effect of this semi-intensive chemotherapy on the patient and his stem cell collections. When available, post-ASCT samples were also investigated.
PCR methodology for detection of residual malignant cells
Detection of the IgH rearranged band at diagnosis: The DNA extracted from the original lymph node was amplified using different consensus VH primers: FR1c, 20 FR2c 20 or FR3c 21 and a JH consensus 3′ primer. 21 When amplification could be done with FR3/JH, a probe was directly made according to our previously described method. [21] [22] [23] In parallel, sequencing of the CDR-III region was performed according to the method used in the laboratory 24 which consists of a direct fluorescence-based methodology with the Prism Sequenase Terminator Single-Stranded DNA Sequencing kit and the ABI 373 apparatus (Applied Biosystems, Foster City, CA, USA). This allowed designing an allele-specific oligomer (ASO) matching the D-N-J sequence for use in a limiting dilution analysis (LDA).
Follow-up sample analysis: Assessment of sample contamination was performed using a two-step methodology, from the simplest to the most complex when needed. First, sample contamination by malignant cells was assayed by amplification with two consensus primers, one of which was labeled with a blue fluorochrome. PCR products were analyzed by electrophoresis through a 6% polyacrylamide gel under denaturing (8M urea) conditions on a ABI 373 (Applied Biosystems), using the GeneScan 672 software, according to methods already described. 25, 26 As long as the original rearranged band persisted, which in our hands corresponds to a percentage of at least 1%, no further analysis was performed and contamination was estimated using the value of the peak ( Figure 1 ). When no signal was observed (corresponding to fewer than 1% malignant cells), a semiquantitative PCR assay was done as described previously [21] [22] [23] to verify whether MCL cells were still detectable, the sensitivity of the method being 1:10 4 to 1:10 5 ( Figure 2 ). If residual malignant cells were identified, a LDA, derived from methods described by other authors 27, 28 was performed, to better evaluate the number of residual lymphoma cells.
Limiting dilution analysis by PCR: DNA extracted from the initial sample was serially diluted into DNA extracted from a pool of normal PBL. One log dilutions (from 1:1 to 1: 10 5 ) were made and 0.6 g DNA of each dilution (corresponds roughly to 10 5 double-stranded molecules) used in a PCR reaction. The PCR conditions common to all patients were as follows: a hot start using Taq Gold Polymerase (Perkin Elmer, Norwalk, CT, USA) followed by 10 cycles of touch-down (0.5°C decrease of the Tm by cycle) and finally 45 cycles at the same melting temperature (Tm). On these dilutions of the original sample, individual PCR conditions were adjusted for each patient, the following parameters being tested: the use of FR3, FR1 or VH familyspecific FR1 primers as 5′ primers, the DMSO concentration (0, 5 or 10%) and the Tm. This individual adjustment was performed in order to have a PCR capable of detecting a single cell per tube, without a specificity. Ten replicates of the 1/10 5 dilution (which corresponds to one target double-strand molecule per tube) were performed and, considering Poisson's statistics, the PCR conditions were considered adequately sensitive if at least five of the 10 replicates showed the expected band. This method was tested for its reproducibility and accuracy. Briefly, when one changed the amount of malignant DNA by a factor of 5 (times 5 or divided by 5), the method could not detect these variations reproducibily. However, variations greater than or equal to one log were reproducibly identified, showing that differences greater than one log in the follow-up samples could be interpreted as true differences in the percentage of malignant cells.
Regarding the follow-up samples, the same procedure was used in two steps: first, dilutions down to 1:10 5 were amplified and visualized on the gel (Figure 3) . Then, 10 replicates of the last positive and first negative dilutions were performed (not shown in Figure 3 ) to evaluate the level of residual cells. As a control of the PCR efficiency on follow-up samples, all measurements included a test sample in which a 1/10 5 dilution of the initial DNA was mixed with the DNA to be evaluated, to ensure that no artifact could lead to underestimation of the actual malignant DNA content. The result was considered accurate if the follow-up sample containing the 1/10 5 dilution of initial DNA was positive.
Results
Molecular results
Using the above described set of primers, 12 (86%) rearrangements could be picked-up using FR3/JH, one using FR1c/JH and one (P1) could not be amplified using any combination of primers. This makes MCL a disease in which a simple PCR strategy is easy to apply for MRD follow-up. Since FR1c and FR2c were used systematically, both to sequence and to evaluate which approach worked best in LDA, we were able to identify VH and JH subfamily usage in 11 patients. The results were as follows: for the VH regions VH1, four; VH3, five, VH4a, one and VH5, one; and for the JH region JH4, eight, JH5, two and JH6, one.
Patients
Out of the 14 patients studied, seven have currently undergone the whole procedure, of which one could not be followed using any PCR strategy. Among the remaining seven patients, there were two deaths during induction: P8 early in the treatment, P11 of progressive disease after completion of four CHOP courses. In all but one (P1) patient completing the induction regimen, contamination of PBSC after the mobilizing regimen or REG-PB following the last chemotherapy course was investigated and compared to steady-state BM and PB involvement by lymphoma cells. Detailed results of clinical responses and contamination are described in Table 1 and Table 2 . Because of their lack of informativity, P1 and P8 were not considered for evaluation of contamination and therefore do not appear in Table 2 . Because percentage only may be poorly informative with regard to evaluating a patient's response, it should be noted that, in responding patients, the average lymphocyte count dropped profoundly after the first chemotherapy, after which no significant differences were observed in terms of absolute lymphocyte counts at regeneration along the rest of the chemotherapy courses.
In terms of relative contamination of PBPC vs steadystate BM and PB investigated in steady state, either before ASCT when performed or 7 to 14 days later if the treatment ended there, the following observations could be made. Given the methods we have used, if one considers patients in which there was at least a one-log difference between mobilized PBSC and steady-state BM or PB, this phenom- Contamination levels are expressed as the fraction of malignant cells in the sample (10 −2 corresponds to 1%).
enon occurred in 8/12 evaluable patients. In the remaining four, there was one case in CR in which no difference was seen (P2) and two cases with no response (P10, P1) in which all the samples contained more than 1% malignant cells. In other words, out of the 10 evaluable responding patients, significant mobilization of lymphoma cells occurred in 8/10 (80%). In no circumstances was the opposite (a lower percentage of malignant cells in collections) observed. Concerning the impact of contamination on outcome, the number of patients in this study is too small to draw any clinical conclusions.
Discussion
The goal of our study was to assess, in a quantitative manner, the evolution of MRD during treatment in unfavorable prognosis MCL patients and to compare the amount of MRD in the PBSC harvests and in the patient in steady state. It is noteworthy that in MCL, amplification using a single primer pair has an interesting yield of more than 80%, which renders the analysis less tedious than in other types of NHL. This is in agreement with reports by some authors 29 but more than in other reports. 15 In our small series, the first striking observation is the following: during the conventional polychemotherapy phase, after an early initial decrease in the amount of MRD as measured after one to two courses of treatment, the additional courses seem to make little difference to the absolute number of circulating malignant cells in most responding patients. Peripheral blood MRD level did not vary significantly between the end of the first course and completion of polychemotherapy, except in one patient. This reflects the rather poor complete response rate (4/14) achieved with this first phase, and this is comparable to the results reported by several authors in such patients [14] [15] [16] [17] [18] with the exception of one paper 12 where more favorable cases (9/9 responses) may have selected for intensification. This fact suggests that, after an initial short debulking phase with conventional CHOP-like polychemotherapy, prolonging this type of treatment beyond two to three courses may be of little use as far as the number of circulating cells is concerned. Obviously, this might not be true for nodal disease, where prolonging the length of treatment might be more beneficial, but we cannot answer this question since no evaluation of response was performed after one course of chemotherapy. The only possible hint is the rather poor complete response rate (3/12) measured by conventional clinical and imaging techniques observed in patients who did not continue to respond molecularly.
As far as cells mobilized using chemotherapy and G-CSF are concerned, another puzzling observation was made: even though the treatment produced some benefit in the patients, as outlined by the PCR results observed in steady state on PB or BM, PB cells collected after the same phase of treatment, but at the time of regeneration are much more contaminated in most cases. In other words, out of the 10 evaluable responding patients, a significant (at least one log) mobilization of lymphoma cells occurred in 8/10 (80%). To our knowledge, and given the rarity of quantitative data, this is the highest rate of significant malignant cell mobilization in NHL when compared to follicular NHL, where there seem to be no differences 29 and in DLCL where it is around 40-50% (personal unpublished data). It may be argued that a difference of one to two logs may be irrelevant, but only a large clinical trial can decide this. Nevertheless, it should also be taken into account that, if one considers the absolute number of malignant cells reinfused in PBSC transplantation as compared with a theoretical bone marrow transplant, then this one to two logs difference in percentage becomes 10-to 100-fold more important.
In our bad prognosis MCL patients two distinct problems are obvious: first, the lack of efficacy of conventional treatments in reducing the amount of circulating lymphoma cells in the majority of patients, ie to induce true complete remissions in most of them; secondly, the fact that most of the PBSC collections are massively contaminated with large amounts of malignant cells, to an extent that is rarely seen in other lymphoid malignancies (up to 10% of clonal cells in three patients). The latter means that, even if HDCT given as conditioning were efficient in eradicating MCL in the patients (and it may well be so, according to the reports in the literature 15, 18 regarding patients in whom no or very few cells are reinfused), its favorable effect may be counteracted by the large number of MCL cells given back to the patient. It is worth mentioning that in the published series where transplanted patients seem to do better, the authors used in vitro purging of the graft.
14 This raises the question of finding the best way to treat bad prognosis MCL patients before ASCT and of reinfusing as few malignant cells as possible using an efficient in vitro purging procedure. The latter point is also a matter of debate.
In a recent paper, Andersen et al 15 showed the difficulty of achieving PCR negativity after immunologic purging and concluded that this particular technique fails to efficiently eradicate malignant cells in BM harvests from MCL patients. However, the authors used a non-quantitative PCR technique, with a high level of sensitivity. We have demonstrated that detectable MCL cells persist in PBSC or BM at a very high level (around 1%) throughout all treatment phases, except in a very small number of patients. It is therefore very possible that, although effective at depleting a stem cell harvest by a few logs, a purging technique may fail to induce PCR negativity, not because of lack of efficacy, but simply because the starting level of contamination is so high that a 2 to 3 log reduction brings the amount of residual disease to a level (1:10 4 -1:10 5 ) still detectable by PCR. In the absence of quantitative data, this remains hypothetical, but if it were true, such a finding would simply translate into molecular terms the extreme difficulty of achieving a significant level of response in the majority of MCL patients at the time stem cells are harvested, and as a result, of purging the graft of MRD to a level where it becomes undetectable. It is noteworthy that, had we used a qualitative PCR technique, we would have concluded an absence of any effect in all patients, even in the very few where treatment, although not rendering them PCR negative, resulted in a marked decrease in the number of MCL cells.
We conclude that advanced stage MCL is a disease unresponsive to most treatments and that patients may benefit from an autologous transplant procedure. However, due to both a bad in vivo response and a possible malignant cell mobilizing effect of the collection procedure, they are being reinfused with heavily contaminated material. The small number of patients investigated prevents any conclusions about the clinical relevance of this fact being drawn. The beneficial effect of HDCT and the possibly unfavorable effect of malignant cells reinfusion may well cancel each other out in most patients. This emphasizes the need for gene marking studies to look at the source of relapse in such patients, which is the only way to properly address this question. It nevertheless remains important to develop effective strategies aimed at reducing the level of contamination of the graft, which could be evaluated in future phase III protocols.
